Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry

Genes and Development

Volumn 27, Issue 16, 2013, Pages 1739-1751

  Zhu, Yan ^a   Regunath, Kausik ^a   Jacq, Xavier ^b   Prives, Carol ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Babraham Research Campus Babraham   (United Kingdom)

Author keywords

Cisplatin; MDM2; MDMX; P38 ; p53; TAB1

Indexed keywords

BINDING PROTEIN; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN MDM2; PROTEIN MDMX; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 BINDING PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

CISPLATIN; MDM2; MDMX; P38Α; P53; TAB1;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 14; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHOSPHORYLATION; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84882646078     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.212258.112     Document Type: Article

References (76)

1. Basu A., Krishnamurthy S. 2010. Cellular responses to cisplatininduced DNA damage. J Nucleic Acids doi: 10.4061/2010/ 201367.
2. Bertelsen M., Sanfridson A. 2007. TAB1 modulates IL-1a mediated cytokine secretion but is dispensable for TAK1 activation. Cell Signal 19: 646-657.
3. Bettermann K., Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F., Weber A, Weiskirchen R, Liedtke C, Gassler N, et al. 2010. TAK1 suppresses a NEMO-dependent but NF-kB-independent pathway to liver cancer. Cancer Cell 17: 481-496.
4. Biderman L., Poyurovsky MV, Assia Y, Manley JL, Prives C. 2012. MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress. Mol Cell Biol 32: 1214-1225.
5. Bragado P., Armesilla A, Silva A, Porras A. 2007. Apoptosis by cisplatin requires p53 mediated p38a MAPK activation through ROS generation. Apoptosis 12: 1733-1742.
6. Bulavin D.V., Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E., Fornace AJ Jr. 1999. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 18: 6845-6854.
7. Chang M.Y., Ho FM, Wang JS, Kang HC, Chang Y, Ye ZX, Lin WW. 2010. AICAR induces cyclooxygenase-2 expression through AMP-activated protein kinase-transforming growth factor-b-activated kinase 1-p38 mitogen-activated protein kinase signaling pathway. Biochem Pharmacol 80: 1210-1220.
8. Chen J. 2012. The roles of MDM2 and MDMX phosphorylation in stress signaling to p53. Genes Cancer 3: 274-282.
9. Chen L., Gilkes DM, Pan Y, Lane WS, Chen J. 2005. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J 24: 3411-3422.
10. Conner S.H., Kular G, Peggie M, Shepherd S, Schuttelkopf AW, Cohen P., Van Aalten DM. 2006. TAK1-binding protein 1 is a pseudophosphatase. Biochem J 399: 427-434.
11. Cuadrado A., Lafarga V, Cheung PC, Dolado I, Llanos S, Cohen P, Nebreda AR. 2007. A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis. EMBO J 26: 2115-2126.
12. Cuenda A., Rousseau S. 2007. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358-1375.
13. Dhillon A.S., Hagan S, Rath O, Kolch W. 2007. MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290.
14. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S., Gostissa M, Coen S, Marchetti A, Del Sal G, et al. 2002. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4: 11-19.
15. Gartel A.L., Tyner AL. 2002. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649.
16. Ge B., Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, Han J. 2002. MAPKK-independent activation of p38a mediated by TAB1-dependent autophosphorylation of p38a. Science 295: 1291-1294.
17. Gilkes D.M., Pan Y, Coppola D, Yeatman T, Reuther GW, Chen J. 2008. Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol 28: 1999-2010.
18. Han J., Sun P. 2007. The pathways to tumor suppression via route p38. Trends Biochem Sci 32: 364-371.
19. Herrero-Martin G, Hoyer-Hansen M, Garcia-Garcia C, Fumarola C, Farkas T, Lopez-Rivas A, Jaattela M. 2009. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J 28: 677-685.
20. Inagaki M., Komatsu Y, Scott G, Yamada G, Ray M, Ninomiya-Tsuji J., Mishina Y. 2008. Generation of a conditional mutant allele for Tab1 in mouse. Genesis 46: 431-439.
21. Inokuchi S., Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K., Akira S, Brenner DA, Seki E. 2010. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci 107: 844-849.
22. Janicke R.U., Sohn D, Schulze-Osthoff K. 2008. The dark side of a tumor suppressor: Anti-apoptotic p53. Cell Death Differ 15: 959-976.
23. Jin Y., Lee H, Zeng SX, Dai MS, Lu H. 2003. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J 22: 6365-6377.
24. Jin Y., Dai MS, Lu SZ, Xu Y, Luo Z, Zhao Y, Lu H. 2006. 14-3-3g binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. EMBO J 25: 1207-1218.
25. Johnson G. 2002. Signal transduction. Scaffolding proteins-more than meets the eye. Science 295: 1249-1250.
26. Kanei-Ishii C, Ninomiya-Tsuji J, Tanikawa J, Nomura T, Ishitani T, Kishida S, Kokura K, Kurahashi T, Ichikawa-Iwata E, Kim Y, et al. 2004. Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes Dev 18: 816-829.
27. Kawai H., Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. 2003. DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 278: 45946-45953.
28. Kelland L. 2007. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584.
29. Kim S.J., Hwang SG, Shin DY, Kang SS, Chun JS. 2002. p38 kinase regulates nitric oxide-induced apoptosis of articular chondrocytes by accumulating p53 via NFkB-dependent transcription and stabilization by serine 15 phosphorylation. J Biol Chem 277: 33501-33508.
30. Komatsu Y., Shibuya H, Takeda N, Ninomiya-Tsuji J, Yasui T, Miyado K., Sekimoto T, Ueno N, Matsumoto K, Yamada G. 2002. Targeted disruption of the Tab1 gene causes embryonic lethality and defects in cardiovascular and lung morphogenesis. Mech Dev 119: 239-249.
31. Konishi N., Nakamura M, Kishi M, Ishida E, Shimada K, Matsuyoshi S., Nagai H, Emi M. 2003. Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci 94: 764-768.
32. Kruse J.P., Gu W. 2009. Modes of p53 regulation. Cell 137: 609-622.
33. Kurosu T., Takahashi Y, Fukuda T, Koyama T, Miki T, Miura O. 2005. p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide. Apoptosis 10: 1111-1120.
34. Landstrom M. 2010. The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol 42: 585-589.
35. Li J., Miller EJ, Ninomiya-Tsuji J, Russell RR 3rd, Young LH. 2005. AMP-activated protein kinase activates p38 mitogenactivated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ Res 97: 872-879.
36. Lu G., Kang YJ, Han J, Herschman HR, Stefani E, Wang Y. 2006. TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling. J Biol Chem 281: 6087-6095.
37. Lu M., Lin SC, Huang Y, Kang YJ, Rich R, Lo YC, Myszka D, Han J, Wu H. 2007a. XIAP induces NF-kB activation via the BIR1/ TAB1 interaction and BIR1 dimerization. Mol Cell 26: 689-702.
38. Lu X., Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. 2007b. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12: 342-354.
39. Malmlof M., Roudier E, Hogberg J, Stenius U. 2007. MEK-ERKmediated phosphorylation of Mdm2 at Ser-166 in hepatocytes. Mdm2 is activated in response to inhibited Akt signaling. J Biol Chem 282: 2288-2296.
40. Mancini F., Moretti F. 2009. Mitochondrial MDM4 (MDMX): An unpredicted role in the p53-mediated intrinsic apoptotic pathway. Cell Cycle 8: 3854-3859.
41. Mancini F., Gentiletti F, D'AngeloM, Giglio S, Nanni S, D'Angelo C, Farsetti A, Citro G, Sacchi A, Pontecorvi A, et al. 2004. MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis. J Biol Chem 279: 8169-8180.
42. Mancini F., Di Conza G, Pellegrino M, Rinaldo C, Prodosmo A, Giglio S., D'Agnano I, Florenzano F, Felicioni L, Buttitta F, et al. 2009. MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J 28: 1926-1939.
43. Marine J.C., Lozano G. 2010. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 17: 93-102.
44. Marine J.C., Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. 2006. Keeping p53 in check: Essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13: 927-934.
45. Marti A., Wirbelauer C, Scheffner M, Krek W. 1999. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1: 14-19.
46. Mayo L.D., Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar C.K., Donner DB. 2005. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 280: 25953-25959.
47. Melisi D., Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A., Abbruzzese JL, Chiao PJ. 2011. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst 103: 1190-1204.
48. Mendoza H., Campbell DG, Burness K, Hastie J, Ronkina N, Shim J.H., Arthur JS, Davis RJ, Gaestel M, Johnson GL, et al. 2008. Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. Biochem J 409: 711-722.
49. Migliorini D., Lazzerini Denchi E, Danovi D, Jochemsen A, Capillo M., Gobbi A, Helin K, Pelicci PG, Marine JC. 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22: 5527-5538.
50. Momcilovic M., Hong SP, Carlson M. 2006. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem 281: 25336-25343.
51. Neil J.R., Schiemann WP. 2008. Altered TAB1:IkB kinase interaction promotes transforming growth factor b-mediated nuclear factor-kB activation during breast cancer progression. Cancer Res 68: 1462-1470.
52. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, Shiina M., Mihara M, Tsuchiya M, Matsumoto K. 2003. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 278: 18485-18490.
53. Oda K., Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H., Tamai K, Tokino T, Nakamura Y, et al. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862.
54. Okamoto K., Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A, Teunisse A., Migliorini D, Kitabayashi I, Marine JC, et al. 2005. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol 25: 9608-9620.
55. Ono K., Ohtomo T, Sato S, Sugamata Y, Suzuki M, Hisamoto N, Ninomiya-Tsuji J, Tsuchiya M, Matsumoto K. 2001. An evolutionarily conserved motif in the TAB1 C-terminal region is necessary for interaction with and activation of TAK1 MAPKKK. J Biol Chem 276: 24396-24400.
56. Parant J., Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29: 92-95.
57. Pereg Y., Shkedy D, de Graaf P, Meulmeester E, Edelson-Averbukh M, Salek M, Biton S, Teunisse AF, Lehmann WD, Jochemsen AG, et al. 2005. Phosphorylation of Hdmx mediates its Hdm2-and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci 102: 5056-5061.
58. Poyurovsky M.V., Jacq X, Ma C, Karni-Schmidt O, Parker PJ, Chalfie M., Manley JL, Prives C. 2003. Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. Mol Cell 12: 875-887.
59. Prickett T.D., Ninomiya-Tsuji J, Broglie P, Muratore-Schroeder TL, Shabanowitz J, Hunt DF, Brautigan DL. 2008. TAB4 stimulates TAK1-TAB1 phosphorylation and binds polyubiquitin to direct signaling to NF-kB. J Biol Chem283: 19245-19254.
60. Rinaldo C., Prodosmo A, Mancini F, Iacovelli S, Sacchi A, Moretti F., Soddu S. 2007. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell 25: 739-750.
61. Shadfan M., Lopez-Pajares V, Yuan ZM. 2012. MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res 1: 88-89.
62. Sheridan C., Brumatti G, Elgendy M, Brunet M, Martin SJ. 2010. An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene 29: 6428-6441.
63. Shibuya H., Yamaguchi K, Shirakabe K, Tonegawa A, Gotoh Y, Ueno N., Irie K, Nishida E, Matsumoto K. 1996. TAB1: An activator of the TAK1 MAPKKK in TGF-b signal transduction. Science 272: 1179-1182.
64. Shim J.H., Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, et al. 2005. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 19: 2668-2681.
65. Thakur N., Sorrentino A, Heldin CH, Landstrom M. 2009. TGFb uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells. Future Oncol 5: 1-3.
66. Urist M., Tanaka T, Poyurovsky MV, Prives C. 2004. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 18: 3041-3054.
67. Vousden K.H., Prives C. 2009. Blinded by the light: The growing complexity of p53. Cell 137: 413-431.
68. Wade M., Wang YV, Wahl GM. 2010. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20: 299-309.
69. Wagner E.F., Nebreda AR. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549.
70. Waning D.L., Lehman JA, Batuello CN, Mayo LD. 2010. Controlling the Mdm2-Mdmx-p53 circuit. Pharmaceuticals (Basel) 3: 1576-1593.
71. Wood C.D., Thornton TM, Sabio G, Davis RA, Rincon M. 2009. Nuclear localization of p38 MAPK in response to DNA damage. Int J Biol Sci 5: 428-437.
72. Wu GS. 2004. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 3: 156-161.
73. Yamaguchi K., Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T., Nishida E, Matsumoto K. 1995. Identification of a member of the MAPKKK family as a potential mediator of TGF-b signal transduction. Science 270: 2008-2011.
74. Yamaguchi K., Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K., Ueno N, Nishida E, Shibuya H, Matsumoto K. 1999. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J 18: 179-187.
75. Zhang X., Lin L, Guo H, Yang J, Jones SN, Jochemsen A, Lu X. 2009. Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response. Cancer Res 69: 7960-7968.
76. Zhu Y., Poyurovsky MV, Li Y, Biderman L, Stahl J, Jacq X, Prives C. 2009. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell 35: 316-326.